Lannett: Citron Exposes the Lawsuits that will Wipe Out the Equity

, ,

Lannett will be the First Pharma Company to go Bankrupt amid Continuing Drug Pricing Scrutiny

If Even Modest Price Cuts Hit Either of Lannett’s Cash Cow Drugs, It Will Violate Its Debt Covenants 

$13-$15 Near Term Target

Equity Worthless Over Long-Term

In the past month we have seen a series of lawsuits against Lannett that Wall Street has completely overlooked.  These lawsuits, along with the Trump administration’s dedication to confront indiscriminate drug price raises, illuminates a clear path to 0 for the equity of Lannett.

For the rest of the story you won’t read anywhere else, click here …